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NMDA receptors are tetrameric ligand-gated ion
channels comprised of GluN1, GluN2, and GluN3
subunits. Two different GluN2 subunits have been
identified in most NMDA receptor-expressing cells,
and themajority of native receptors are triheteromers
containing two GluN1 and two different GluN2. In
contrast to diheteromeric NMDA receptors, little is
known about the function of triheteromers.We devel-
oped a method to provide selective cell-surface
expression of recombinant GluN1/GluN2A/GluN2B
triheteromers and compared properties of these re-
ceptors with those of GluN1/GluN2A and GluN1/
GluN2B diheteromers. We show that glutamate
deactivation of triheteromers is distinct from those
of GluN1/GluN2A and GluN1/GluN2B and reveal
modulation of triheteromers by subunit-selective
antagonists ifenprodil, CP-101,606, TCN-201, and
extracellular Zn2+. Furthermore, kinetic measure-
ments suggest variation in the ifenprodil binding
site of triheteromers compared to GluN1/GluN2B
diheteromers. This work provides insight into the
distinct properties of GluN1/GluN2A/GluN2B trihe-
teromers, which are presumably the most abundant
NMDA receptors in the adult forebrain.
INTRODUCTION
NMDA receptors are ionotropic glutamate receptors that are crit-
ically involved in many processes in the central nervous system
(CNS), including neuronal development, memory, and learning
(Traynelis et al., 2010). However, they are also implicated in a
multitude of psychiatric and neurological disorders, such as
schizophrenia, depression, epilepsy, stroke, and traumatic brain
injury, as well as Parkinson’s, Huntington’s, and Alzheimer’s dis-
eases (Paoletti et al., 2013; Traynelis et al., 2010). NMDA recep-
tors are therefore widely considered as important targets for
therapeutic intervention in many diseases of the CNS.
Seven NMDA receptor subunits have been cloned: GluN1,
GluN2A–D, and GluN3A–B. The majority of native NMDA recep-1084 Neuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc.tors are tetrameric assemblies of two GluN1 subunits and two
GluN2 subunits (Traynelis et al., 2010). GluN3 can also assemble
with GluN1 and GluN2, but the stoichiometry of GluN3-contain-
ing receptors is unknown. Studies on recombinant NMDA recep-
tors almost exclusively describe diheteromeric receptors that
are assembled from GluN1 and only one type of GluN2. How-
ever, at least two different GluN2 subunits have been identified
in most, if not all, NMDA receptor-expressing cells. Furthermore,
a compelling body of evidence shows that a large proportion of
native NMDA receptors are triheteromers assembled from two
GluN1 and two different GluN2 subunits. In particular, it has
been demonstrated that GluN1/GluN2A/GluN2B triheteromers
account for >50% of the total NMDA receptors in hippocampus
and cortex of the adult rodent brain (Al-Hallaq et al., 2007; Luo
et al., 1997; Rauner and Ko¨hr, 2011; Sheng et al., 1994; Tovar
et al., 2013; but see also Chazot and Stephenson, 1997). Despite
the prevalence of triheteromeric NMDA receptors in vivo, there is
a fundamental gap in our knowledge of their function and phar-
macology because of our inability to faithfully express these
triheteromeric receptors in heterologous expression systems
without accompanying diheteromeric receptors (Chazot et al.,
1994; Hatton and Paoletti, 2005; Tovar and Westbrook, 1999;
Vicini et al., 1998).
Coexpression of GluN1 with two different GluN2 subunits
(e.g., GluN2A and GluN2B) in heterologous systems generates
three populations of functional NMDA receptors consisting
of two different diheteromeric receptors (e.g., GluN1/GluN2A
and GluN1/GluN2B), as well as triheteromeric receptors (e.g.,
GluN1/GluN2A/GluN2B). Expression of three receptor popula-
tions confounds studies on the properties of triheteromeric re-
ceptors. To mitigate this problem, we exploited the trafficking
control system of the G protein-coupled GABAB receptors that
are heterodimers composed of GABAB1 and GABAB2 subunits
(Bettler et al., 2004). The GABAB1 subunit possesses a retention
signal (RXR motif) in the intracellular C-terminal domain (CTD)
that retains the subunit in the endoplasmic reticulum (ER) and
thus prevents expression of homomeric GABAB1 at the cell sur-
face (Margeta-Mitrovic et al., 2000). However, the retention
signal is masked through a coiled-coil interaction with GABAB2
between leucine zipper motifs within in the CTDs, allowing traf-
ficking of the heterodimer to the cell surface (Margeta-Mitrovic
et al., 2000). With some modifications, the GABAB receptor
trafficking system has been utilized to express heterodimeric
metabotropic glutamate receptors in heterologous systems
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et al., 2004).
We took advantage of the GABAB receptor leucine zipper
motifs and engineered C-terminal peptide tags that were used
to selectively express recombinant triheteromeric receptors at
the cell-surface without confounding coexpression of dihetero-
meric receptors. Thus, this approach enables quantitative eval-
uation of functional and pharmacological properties of GluN1/
GluN2A/GluN2B triheteromeric receptors.
RESULTS
Selective Cell-Surface Expression of Triheteromeric
GluN1/GluN2A/GluN2B Receptors
In order to selectively express triheteromeric NMDA receptors at
the cell surface, we engineered two different C-terminal peptide
tags composed of the leucine zipper motifs from GABAB1 and
GABAB2 (LZ1 and LZ2, respectively) immediately followed by
C-terminal dilysine KKXX ER retention/retrieval motifs (Figure 1A;
Figure S1 available online). The leucine zipper motifs of GABAB1
and GABAB2 can interact to form a parallel heterodimeric coiled-
coil structure (Kammerer et al., 1999). The KKXX motifs at the
distal C termini will localize the subunits in the endoplasmic retic-
ulum (ER) (Zerangue et al., 2001) unless masked by coiled-coil
formation between LZ1 and LZ2 (Brock et al., 2005). Finally,
we added a peptide linker (L4) to the N termini to generate the
tags L4-LZ1-KKXX and L4-LZ2-KKXX (hereafter, C1 and C2,
respectively). The L4 peptide linker was composed of four re-
peats of amino acids EAAAK, which will generate a rigid a-helical
rod (Arai et al., 2004). Fusing C1 and C2 to the intracellular C
termini of GluN2 subunits should allow selective surface expres-
sion of NMDA receptors composed of two GluN1, one C1-
tagged GluN2, and one C2-tagged GluN2 (Figure 1B). To avoid
potential incompatibility between trafficking signals present in
GluN2A and GluN2B CTDs and between CTD structures and
spatial requirements for the C1/C2 interaction, we replaced the
CTD of GluN2B with that of GluN2A (Figure 1A). The functional
properties of GluN2B subunits containing the CTD of GluN2A
are indistinguishable from those of wild-type GluN2B (Maki
et al., 2012; Punnakkal et al., 2012). Thus, we generated C1-
and C2-tagged GluN2A and GluN2B subunits (2AC1, 2AC2,
2BAC1, and 2BAC2) that only differ in the intracellular CTDs by
the leucine zipper motifs (LZ1 and LZ2). The amino acid se-
quences for the C1 and C2 peptide tags are shown in Figure S1.
Coexpression of 2AC1 and 2BAC2 (aswell as GluN1) in Xenopus
oocytes produced robust current responses activated by gluta-
mate plus glycine that increased in amplitude on days 1–3,
following cRNA injection, and remained constant on days 4–6
(Figures 1C and 1D). In theory, the glutamate/glycine-activated
currents from oocytes coexpressing 2AC1, 2BAC2, and GluN1
are mediated by NMDA receptors composed of one 2AC1 and
one 2BAC2 with masked retention signals, as well as two GluN1
subunits (hereafter, 2AC1/2BAC2). However, some 2AC1/2AC1
and 2BAC2/2BAC2 receptors that may have escaped ER retention
could also contribute to the measured current responses. To
evaluate the fraction of the total current response that is
mediated by escaped receptors (i.e., ‘‘escape’’ current), we
generated 2AC1 and 2BAC2 subunits withmutations in the agonistbinding pocket that abolish glutamate binding (R518K + T690I in
2AC1(RK+TI) and R519K + T691I in 2BAC2(RK+TI)) (Erreger et al.,
2007; Hatton and Paoletti, 2005; Laube et al., 1997). Coexpres-
sion of 2AC1 and 2BAC2(RK+TI) produces only one population of re-
ceptors that can be activated by 100 mM glutamate, namely,
escaped 2AC1/2AC1, because agonist occupancy at two GluN2
subunits are required for NMDA receptor activation (Benveniste
and Mayer, 1991; Clements and Westbrook, 1991) (Figures 1C
and 1D). Thus, comparison of current responses from oocytes
expressing 2AC1/2BAC2with responses from oocytes coexpress-
ing 2AC1/2BAC2(RK+TI) allows estimation of the fractional current
mediated by escaped 2AC1/2AC1. Similarly, comparison to
current responses from oocytes expressing 2AC1(RK+TI)/2BAC2
allows estimation of the fractional current mediated by escaped
2BAC2/2BAC2 (Figures 1C and 1D). The sum of the fractional cur-
rents from escaped 2AC1/2AC1 and 2BAC2/2BAC2 assessed using
this approach will provide an estimate of the percent ‘‘escape’’
current in oocytes coexpressing 2AC1 and 2BAC2 that is medi-
ated by receptors other than triheteromeric 2AC1/2BAC2. For
the 2AC1/2BAC2 subunit combination, the percent ‘‘escape’’ cur-
rent was between 3%–7% on days 2–4 of expression (five
batches of oocytes, n = 6 oocytes each day for each batch) (Fig-
ure 1E). Similar results were obtained for 2AC1/2AC2 and 2BAC1/
2BAC2 subunit combinations (Figure 1E; see also Figure S1).
To provide an alternative evaluation of the efficiency by
which the engineered peptide tags express a homogenous pop-
ulation of triheteromeric receptors, we introduced a mutation in
the agonist binding pocket that reduces glutamate potency
(H485A in GluN2A and H486A in GluN2B) (Anson et al., 1998;
Hansen et al., 2005). If there is observable ‘‘escape’’ current,
then glutamate concentration-response data from oocytes
coexpressing wild-type and mutated subunits will have three
components mediated by receptors with one binding site
mutated as well as escaped wild-type and double mutant recep-
tors. Thus, this approach will allow evaluation of an ‘‘escape’’
current in individual oocytes by assessing the fractional sizes
of the components in the glutamate concentration-response
data (see Figures S2 and S3; Table S1). The results obtained
using this approach to evaluate the efficiency of the peptide
tags were consistent with ‘‘escape’’ currents estimated using
the ‘‘RK+TI’’ mutations.
In summary, we have engineered peptide tags (C1 and C2)
that upon fusion to the C terminus of GluN2A and GluN2B
subunits facilitate selective expression of NMDA receptors with
a defined subunit combination at the cell-surface, thereby
enabling experiments on a homogenous population of trihetero-
meric GluN1/GluN2A/GluN2B receptors.
Inhibition of Triheteromeric Receptors by
GluN2A-Selective Modulators
The lack of information regarding properties of triheteromeric
receptors has been a major obstacle in studies using subtype-
selective antagonists to assess the physiological roles of native
NMDA receptors. Moreover, the inability to study triheteromeric
NMDA receptors that are abundant in the adult brain compli-
cates clinical development of subunit-selective modulators. By
controlling the subunit composition of cell-surface-expressed
receptors using the engineered peptide tags, we can begin toNeuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc. 1085
Figure 1. Control of NMDA Receptor Composition Using Engineered Peptide Tags
(A) Linear representations of polypeptide chains show the amino terminal domain (ATD), S1 and S2 segments of the agonist binding domain, transmembrane
helices (M1, M3, and M4), and the re-entrant pore loop (M2) of GluN2A, GluN2B, GluN2A with C1- or C2-tags fused to the intracellular C terminus (2ACX), and
chimeric GluN2B subunits with the C-terminal domain replaced by that of C1- or C2-tagged GluN2A (2BACX).
(B) Coexpression of GluN1 (omitted from cartoon for clarity) with two different GluN2 subunits in heterologous systemswould normally generate three populations
of functional NMDA receptors. However, fusing the C1 and C2 tags to the intracellular C-termini of GluN2 subunits should not allow cell-surface expression of
receptors that contain two C1-tagged or two C2-tagged GluN2 subunits.
(C) Representative two-electrode voltage-clamp recordings of responses from recombinant NMDA receptors expressed inXenopus oocytes activated by 100 mM
glutamate plus 50 mMglycine. GluN1 was coexpressed with 2AC1 andmutated 2BAC2 (R519K + T691I in 2BAC2(RK+TI)), mutated 2AC1 (R518K + T690I in 2AC1(RK+TI))
and 2BAC2, or 2AC1 and 2BAC2. The RK+TI mutations abolish binding of glutamate and render any NMDA receptor containing this subunit nonfunctional.
(D) Coexpression of 2AC1 and 2BAC2 (as well as GluN1) produced robust currents responses that increased following cRNA injection (black), whereas current
responses from 2AC1/2AC1 and 2BAC2/2BAC2 receptors that may have escaped ER retention remained small. Data are mean ± SEM, and each data point is from
five batches of oocytes with six oocytes for each batch (n = 30).
(E) The sum of the fractional currents assessed using the RK+TI mutations provided an estimate of the percent ‘‘escape’’ current in oocytes coexpressing 2AC1
and 2BAC2, 2AC1 and 2AC2, or 2BAC1 and 2BAC2.
See also Figures S1–S3 and Table S1.
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tors at GluN1/GluN2A/GluN2B triheteromers.
We examined the GluN2A-selective antagonist TCN-201,
which is a negative allosteric modulator of glycine binding to
GluN1 (Bettini et al., 2010; Hansen et al., 2012). The presence1086 Neuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc.of the peptide tags in the CTD did not alter potency and maximal
inhibition for TCN-201 at 2AC1/2AC2 compared to wild-type 2A/
2A, and TCN-201 did not display any activity at wild-type 2B/
2B and 2BAC1/2BAC2 receptors (Figure 2A; Table 1). However,
the IC50 of TCN-201 increased from 370 ± 30 nM at wild-type
Figure 2. Inhibition of Triheteromeric Receptors by GluN2A-Selective Antagonists
(A) TCN-201 data were generated for wild-type receptors (wild-type [WT] 2A/2A and WT 2B/2B) and receptors containing C1- and C2-tagged GluN2 subunits
expressed in Xenopus oocytes using two-electrode voltage-clamp recordings. Current responses were activated by 100 mM glutamate plus 3 mM glycine. Data
are mean ± SEM from 8–10 oocytes.
(B) Data for inhibition by extracellular Zn2+ were generated for the NMDA receptor subtypes. Current responses were activated by 50 mM glutamate plus 50 mM
glycine. Data are from 6–12 oocytes.
(C–E) Inhibition of wild-type GluN1/GluN2A (WT 2A/2A) and GluN1/GluN2A/GluN2B triheteromers (2AC1/2BAC2) by extracellular Zn
2+ was compared at pH 7.8,
7.3, and 6.8. Data are from 6–28 oocytes.
(F and G) The representative recordings show inhibition by extracellular Zn2+ at physiological pH 7.3.
(H) Data for inhibition by extracellular Zn2+ at physiological pH 7.3 of receptors with a mutation in a single or at both Zn2+ binding sites (H128S in GluN2A and
H127A in GluN2B). The blue dashed line represents the fit of actual data from 2AC1/2BAC2 shown in (D). Data are from 6–11 oocytes.
See also Table 1 and Figure S4.
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(n = 10) and maximal inhibition was reduced from 91% ± 1%
to 72% ± 4% (Figure 2A; Table 1). Thus, the presence of a single
GluN2A subunit in triheteromers reduces TCN-201 inhibition
compared to receptors with two GluN2A subunits. TCN-201 in-
hibition of 2AC1/2BAC2 and 2AC2/2BAC1 triheteromers (i.e., the
C1- and C2-tags were swapped between the GluN2A and
GluN2B subunits) was not significantly different (Figure S4).Extracellular Zn2+ can inhibit NMDA receptors at low nanomo-
lar concentrations in a voltage-independent manner by binding
to a high-affinity site in the amino-terminal domain (ATD) of
GluN2A (Choi and Lipton, 1999; Paoletti et al., 2000). In addition,
Zn2+ inhibition can occur through binding to the GluN2B ATD,
albeit at higher micromolar concentrations (Karakas et al.,
2009; Rachline et al., 2005). Extracellular Zn2+ can also produce
a nonspecific voltage-dependent channel block through bindingNeuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc. 1087
Table 1. Concentration Response Data for NMDA Receptor Modulators
WT 2A/2A 2AC1/2AC2 2AC1/2BAC2
IC50 (nM) Max %
Inhibition
Hill Slope n IC50 (nM) Max %
Inhibition
Hill Slope n IC50 (nM) Max %
Inhibition
Hill Slope n
TCN-201 370 ± 30 91 ± 1 1.3 8 360 ± 20 94 ± 1 1.4 10 1,350 ± 130 72 ± 4 1.5 8
Zn2+ (pH 7.8) 62 ± 4 29 ± 1 1.1 10 nd – – – 63 ± 7 30 ± 1 1.0a 10
Zn2+ (pH 7.3) 61 ± 4 57 ± 2 1.0 18 69 ± 5 59 ± 3 0.9 10 58 ± 2 49 ± 1 0.8 28
Zn2+ (pH 6.8) 47 ± 2 93 ± 2 0.8 6 nd – – – 57 ± 5 65 ± 1 0.8 10
WT 2B/2B 2BAC1/2BAC2 2AC1/2BAC2
Ifenprodil 72 ± 8 88 ± 2 1.0 8 71 ± 7 88 ± 2 1.0 6 450 ± 30 32 ± 1 1.1 16
Ifenprodil (+Zn2+) 54 ± 3 88 ± 2 1.0 6 nd – – – 200 ± 20 50 ± 2 1.1 8
CP-101,606 61 ± 3 89 ± 1 1.5 8 71 ± 5 87 ± 2 1.6 7 220 ± 20 29 ± 2 1.4 9
CP-101,606 (+Zn2+) 46 ± 3 90 ± 1 1.3 6 nd – – – 120 ± 10 58 ± 2 1.6 8
Data were generated using two-electrode voltage-clamp recordings of responses from Xenopus oocytes coexpressing GluN1, together with wild type
(WT 2A/2A andWT 2B/2B) or C1- andC2-taggedGluN2 subunits. Data aremean ±SEM. n is the number of oocytes used to generate the data. Maximal
inhibition was obtained from the fitted maximal inhibition at saturating concentrations of antagonist. nd, not determined.
aIndicates that the Hill slope was fixed to one during fitting of the data.
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a significant role of Zn2+ as an endogenous NMDA receptor
modulator (Nozaki et al., 2011; Sensi et al., 2011), little is known
about its actions on GluN1/GluN2A/GluN2B triheteromers. One
previous study reported inhibition of triheteromers by extracel-
lular Zn2+ in the nanomolar range but could not provide robust
values for potency and efficacy (Hatton and Paoletti, 2005).
Because inhibition by extracellular Zn2+ is considered relevant
for the physiological function of GluN2A-containing NMDA re-
ceptors (Sensi et al., 2011), we decided to determine the potency
and efficacy at triheteromers. To minimize the voltage-depen-
dent, low-affinity component of Zn2+ inhibition, we recorded at
a holding potential of 20 mV and Zn2+ concentrations were
kept below 300 nM. Under these conditions, we did not observe
differences between Zn2+ inhibition of wild-type 2A/2A and 2AC1/
2AC2, as well as wild-type 2B/2B and 2BAC1/2BAC2, supporting
the idea that neither the GluN2A CTD in GluN2B nor the peptide
tags change receptor properties (Figure 2B; Table 1). At
physiological pH 7.3, Zn2+ displayed high-potency inhibition of
wild-type 2A/2A with an IC50 value of 61 ± 4 nM and a maximal
inhibition of 57% ± 2% (n = 18), consistent with previous reports
(Low et al., 2000; Paoletti et al., 1997; Traynelis et al., 1998;
Williams, 1996). At a concentration of 265 nM, extracellular
Zn2+ reduced responses from wild-type 2B/2B to 80% ± 1%
(n = 6) of control (Figure 2B; Table 1), consistent with minimal
voltage-dependent channel block and inhibition primarily medi-
ated through binding to the GluN2B ATD (Karakas et al., 2009;
Rachline et al., 2005; Traynelis et al., 1998).
The presence of only a single high-affinity GluN2A binding site
in the 2AC1/2BAC2 triheteromers did not change the potency of
Zn2+ inhibition at physiological pH 7.3 compared to wild-type
2A/2A (Figures 2D, 2F, and 2G; Table 1). The IC50 of extracellular
Zn2+ at 2AC1/2BAC2 triheteromers was 58 ± 2 nM (n = 28)
compared to 61 ± 4 nM (n = 18) at wild-type 2A/2A. However,
there was a reduction in the fitted maximal Zn2+ inhibition of
2AC1/2BAC2 triheteromers (49% ± 1%) compared to wild-type
2A/2A (57% ± 2%). Zn2+ inhibition of 2AC1/2BAC2 and 2AC2/
2BAC1 triheteromers (i.e., the C1- and C2-tags were swapped)1088 Neuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc.was not significantly different (Figure S4). The high-potency
and efficacious inhibition of triheteromers by extracellular Zn2+
was unexpected and suggest that not only GluN1/GluN2A
diheteromers but also GluN1/GluN2A/GluN2B triheteromers in
the adult brain are modulated by endogenous Zn2+.
Binding of Zn2+ to the GluN2A ATD increases proton inhibition
of the NMDA receptor, and Zn2+ binding presumably inhibits the
receptor by increasing proton affinity and thereby the fraction of
protonated, nonfunctional receptors (Choi and Lipton, 1999;
Erreger and Traynelis, 2005, 2008; Low et al., 2000). The func-
tional link between Zn2+ and proton inhibition causes the
maximal Zn2+ inhibition to increase at more acidic pH and
diminish at more alkaline pH. We therefore compared Zn2+
inhibition of 2AC1/2BAC2 triheteromers and wild-type 2A/2A at
a more alkaline pH of 7.8 and a more acidic pH of 6.8
(Figures 2C and 2E; Table 1). Inhibition by Zn2+ at alkaline pH
7.8 was indistinguishable for wild-type 2A/2A and 2AC1/2BAC2
triheteromers with IC50 values of 62 ± 4 nM (n = 10) and 63 ±
7 nM (n = 10), respectively, and maximal inhibition of 29% ±
1% and 30% ± 1%, respectively. By contrast, there were differ-
ences between Zn2+ inhibition of wild-type 2A/2A and 2AC1/
2BAC2 triheteromers at acidic pH 6.8 with IC50 values of 47 ±
2 nM (n = 6) and 57 ± 5 nM (n = 10), respectively, and maximal
inhibition of 93% ± 2% and 65% ± 1%, respectively. These re-
sults suggest that although Zn2+ binds with high affinity to
NMDA receptors with a single GluN2A subunit, binding to a
single site in the receptor is not capable of increasing proton
inhibition to the same extent as binding to two high-affinity sites
as in wild-type 2A/2A.
To evaluate whether Zn2+ binding to the GluN2B ATD contrib-
utes to Zn2+ inhibition of 2AC1/2BAC2 triheteromers, we elimi-
nated Zn2+ binding to GluN2B by mutating a key residue in the
Zn2+ binding site (H127A) (Karakas et al., 2009; Rachline et al.,
2005). There was no marked difference between Zn2+ inhibition
of 2AC1/2BAC2 and mutated 2AC1/2BAC2(H127A) triheteromers
with IC50 values of 58 ± 2 nM (n = 28) and 44 ± 8 nM (n = 6),
respectively, and maximal inhibition of 49% ± 1% and 47% ±
3%, respectively (Figure 2H). Because Zn2+ binding to GluN2B
Neuron
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we evaluated inhibition of GluN1/GluN2A diheteromers with only
a single intact high-affinity site by mutating the putative Zn2+
binding site in one GluN2A subunit (i.e., 2AC1/2AC2(H128S)). In
contrast to 2AC1/2BAC2 triheteromers that contain a single
GluN2A subunit, both potency and maximal inhibition by Zn2+
were markedly reduced for 2AC1/2AC2(H128S) that also possesses
a single high-affinity Zn2+ binding site (Figure 2H). The IC50 for
Zn2+ inhibition of 2AC1/2AC2(H128S) was 120 ± 20 nM andmaximal
inhibition was 21% ± 3% (n = 11). Extracellular Zn2+ did not pro-
duce any inhibition of GluN1/GluN2A diheteromers with both
high-affinity sites mutated (2AC1(H128S)/2AC2(H128S); n = 6),
consistent with the absence of voltage-dependent channel block
by Zn2+ under these experimental conditions (Figure 2H). The
results obtained for GluN1/GluN2A diheteromers with a single
or both Zn2+ binding sites mutated are consistent with previous
reports (Hatton and Paoletti, 2005; Nozaki et al., 2011; Paoletti
et al., 2000). However, the similar Zn2+ inhibition of GluN1/
GluN2A/GluN2B triheteromers and GluN1/GluN2A diheteromers
is unexpected when contrasted with the reduced Zn2+ inhibition
of 2AC1/2AC1(H128S) and invites additional experiments to fully
delineate the mechanism of Zn2+ modulation.
Inhibition of Triheteromeric Receptors by GluN2B-
Selective Modulators
Noncompetitive antagonists that selectively bind at the interface
between GluN1 and GluN2B ATDs (Burger et al., 2012; Karakas
et al., 2011), such as ifenprodil and CP-101,606, have been
extensively explored in the treatment of several neuropatholog-
ical conditions (Traynelis et al., 2010). Recently, these antago-
nists have received renewed interest following the discovery
that CP-101,606 is effective against treatment-resistant depres-
sion (Preskorn et al., 2008). Despite the considerable resources
used in the development of GluN2B-selective antagonists as
therapeutic agents, there is a problematic lack of information
regarding the activity of these ligands at GluN1/GluN2A/GluN2B
triheteromers.
We therefore compared ifenprodil inhibition of triheteromers to
that of GluN1/GluN2A and GluN1/GluN2B diheteromers. We
recorded at a holding potential of 40 mV to minimize nonspe-
cific voltage-dependent inhibition by ifenprodil, which is pro-
nounced at concentrations above 3 mM (Figure S5). Ifenprodil
reduced current responses from wild-type 2B/2B with an IC50
of 72 ± 8 nMandmaximal inhibition of 88%± 2% (n = 8), whereas
responses from wild-type 2A/2A were insensitive to 3 mM ifen-
prodil (n = 10) (Figures 3A and 3B; Table 1). Ifenprodil inhibition
of 2AC1/2BAC2 triheteromers was markedly reduced compared
to wild-type 2B/2B, because IC50 increased 6.3-fold to 450 ±
30 nM and maximal inhibition was 32% ± 1% (n = 16). Ifenprodil
inhibition of 2AC1/2BAC2 and 2AC2/2BAC1 triheteromers (i.e., the
C1- and C2-tags were swapped) was not significantly different
(Figure S4). Thus, the reduced ifenprodil inhibition of trihe-
teromers compared to wild-type 2B/2B is in stark contrast to
the virtually unchanged Zn2+ inhibition of triheteromers
compared to wild-type 2A/2A (Table 1). Studies have suggested
two populations of ifenprodil-sensitive NMDA receptors in the
adult rodent forebrain that have been attributed to GluN1/
GluN2B diheteromers with high sensitivity and GluN1/GluN2A/GluN2B triheteromers with lower sensitivity (Gray et al., 2011;
Kew et al., 1998; Tovar and Westbrook, 1999). Our ability to
quantitatively evaluate the pharmacology of triheteromers
conclusively validates this idea and also demonstrates that
reduced ifenprodil sensitivity of triheteromers is mainly mediated
by a diminished maximal inhibition rather than by a dramatic
reduction in potency (Figures 3A and 3B; Table 1).
To assess whether our findings regarding ifenprodil inhibition
of triheteromers can transfer to other GluN2B-selective antago-
nists, we also evaluated CP-101,606. Responses from wild-type
2B/2Bwas inhibited byCP-101,606with an IC50 of 61 ± 3 nMand
maximal inhibition of 89% ± 1% (n = 8), whereas responses from
wild-type 2A/2A were insensitive to 3 mM CP-101,606 (n = 10)
(Figure 3C; Table 1). CP-101,606 inhibition of 2AC1/2BAC2
triheteromers had a maximal inhibition of 29% ± 2% and an
IC50 of 220 ± 20 nM (n = 9), which is increased 3.6-fold compared
to wild-type 2B/2B. Thus, the presence of a single GluN2B
subunit in 2AC1/2BAC2 triheteromers has a quantitatively similar
outcome for inhibition by ifenprodil and CP-101,606 (Figures
3B and 3C; Table 1).
It has been shown previously that inhibition of triheteromers by
a high concentration of ifenprodil is enhanced by the presence of
extracellular Zn2+, presumably through Zn2+ binding to the single
high-affinity site in the GluN2A ATD (Hatton and Paoletti, 2005).
To study this observation in more detail, we generated ifenprodil
and CP-101,606 concentration-response data in the presence of
300 nM Zn2+. The presence of extracellular Zn2+ resulted in a
slight increase in both ifenprodil and CP-101,606 potencies at
wild-type 2B/2B without affecting maximal inhibition (Figures
3D and 3E; Table 1), whereas wild-type 2A/2A remained insensi-
tive to both ifenprodil (n = 10) and CP-101,606 (n = 10). Ifenprodil
and CP-101,606 potencies were slightly increased at 2AC1/
2BAC2 triheteromers by the presence of extracellular Zn
2+,
whereas a more pronounced effect on maximal inhibition could
be observed. Maximal ifenprodil inhibition increased from
32% ± 1% (n = 16) in the absence of Zn2+ to 50% ± 2% (n = 8)
in the presence of Zn2+, and maximal CP-101,606 inhibition
increased from 29% ± 2% (n = 9) to 58% ± 2% (n = 8) (Figures
3D and 3E; Table 1). This finding is highly relevant to the applica-
tion of GluN2B-selective antagonists as pharmacological tools
or therapeutic agents, because tonic or synaptic Zn2+ have
been suggested to be present during electrophysiological re-
cordings and in normal brain physiology (Paoletti et al., 1997;
Sensi et al., 2011; Traynelis et al., 1998).
Time Course of Ifenprodil Inhibition of GluN1/GluN2A/
GluN2B Receptors
In order to investigate the nature of the ifenprodil binding site in
GluN1/GluN2A/GluN2B triheteromers, we evaluated the kinetics
of ifenprodil inhibition using fast-application whole-cell patch-
clamp recordings. For this purpose, we first optimized the engi-
neered peptide tags to control subunit composition of NMDA
receptors expressed in HEK293 cells (see the Experimental
Procedures). Initially, we measured the time course and con-
centration-dependence of ifenprodil inhibition of steady-state
responses from wild-type 2B/2B (Figure 4A). The onset of ifen-
prodil inhibition of wild-type 2B/2B was adequately described
by a single exponential function to obtain the inhibition timeNeuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc. 1089
Figure 3. Inhibition of Triheteromeric Receptors by GluN2B-Selective Antagonists
(A) The representative two-electrode voltage-clamp recordings show ifenprodil inhibition of 2BAC1/2BAC2 diheteromers and 2AC1/2BAC2 triheteromers expressed
in Xenopus oocytes. Current responses were activated by 100 mM glutamate plus 50 mM glycine.
(B) Data for ifenprodil inhibition were generated for the NMDA receptor subtypes. Data are mean ± SEM from 6–16 oocytes.
(C) Data for CP-101,606 inhibition were generated for the NMDA receptor subtypes. Data are from 7–10 oocytes.
(D and E) Data for ifenprodil and CP-101,606 inhibition were generated in the continuous presence of 300 nM extracellular Zn2+. The blue dashed lines represents
fits of actual data from 2AC1/2BAC2 (control) generated in the absence of extracellular Zn
2+ as shown in (B) and (C). Data are from 6–8 oocytes.
See also Table 1 and Figures S4 and S5.
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptorsconstants (tinhibition). Furthermore, 1/tinhibition was linearly related
to the concentration of ifenprodil (Figure 4C), which is consistent
with a simple bimolecular reaction. The slope of the linear fit to
this relationship therefore provides the rate of ifenprodil binding
(kon), which was 0.263 mM
1,s1 for wild-type 2B/2B (95% con-
fidence interval was 0.236–0.290 mM1,s1; n = 6). Assuming
that unbinding is concentration-independent, the rate of ifen-
prodil unbinding (koff) derived from the y intercept was
0.096 s1 (95% confidence interval was 0.051–0.141 s1).
Thus, the Kd = koff/kon for ifenprodil binding to wild-type 2B/2B
was 370 nM, which is similar to the Kd of 320 nMmeasured using
isothermal titration calorimetry with purified GluN1 and GluN2B
ATDs (Karakas et al., 2011).1090 Neuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc.We next measured the kinetics of ifenprodil inhibition of
steady-state responses from 2AC1/2BAC2 triheteromers (Fig-
ure 4B). Again, the onset of ifenprodil inhibition could be
described by a single exponential function, and 1/tinhibition was
linearly related to the concentration of ifenprodil (Figure 4C).
The rate of ifenprodil binding (kon) was 0.099 mM
1,s1 for
2AC1/2BAC2 triheteromers (95% confidence interval was 0.067–
0.131 mM1,s1; n = 6), which was markedly reduced compared
to wild-type 2B/2B. The rate of ifenprodil unbinding (koff) derived
from the y intercept was 0.065 s1 (95% confidence interval was
0.012–0.119 s1). The Kd for ifenprodil binding to 2AC1/2BAC2
triheteromers was 660 nM, which is increased 1.8-fold
compared to wild-type 2B/2B. These results demonstrate that
Figure 4. Deactivation Time Course of Triheteromers and Rate of Ifenprodil Inhibition
(A) The overlay compares representative whole-cell patch-clamp recordings of current responses from wild-type GluN1/GluN2B (WT 2B/2B) expressed in
HEK293 cells. The receptors are activated by 100 mM glutamate in the continuous presence of 100 mM glycine. The time course of ifenprodil inhibition of
steady-state responses can be described using mono-exponential fits (black lines).
(B) Representative response from GluN1/GluN2A/GluN2B triheteromers (2AC1/2BAC2) activated by 100 mM glutamate in the continuous presence of 100 mM
glycine and inhibited by ifenprodil.
(C) The rate of ifenprodil inhibition (1/tinhibition) was linearly related to the concentration of ifenprodil, and the slope of the linear fit provides the rate of ifenprodil
binding (kon), which was 0.263 mM
1,s1 for wild-type 2B/2B (n = 6) and 0.099 mM1,s1 for 2AC1/2BAC2 triheteromers (n = 6). Data are mean ± SEM.
(D) The overlay compares representative whole-cell patch-clamp recordings of responses normalized to the peak amplitude. The diheteromeric WT 2A/2A and
2B/2B and triheteromeric 2AC1/2BAC2 receptors were expressed in HEK293 cells and activated by brief pulses (5 ms) of 1 mM glutamate in the continuous
presence of 100 mM glycine.
(E) The graph plots the weighted time constants for deactivation following removal of glutamate from individual cells (circles) as well as the mean (horizontal line)
for wild-type 2A/2A (n = 11), 2AC1/2BAC2 triheteromers (n = 17), and wild-type 2B/2B (n = 15). Asterisk denotes significantly different (unpaired t test; two-tailed,
p < 0.05).
See also Tables 2 and S2 and Figure S6.
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kinetics of ifenprodil inhibition are clearly distinct from those of
wild-type 2B/2B. In addition, the inhibition by 2.5 mM ifenprodil
was 36% ± 1% (n = 6) in HEK293 cells expressing 2AC1/2BAC2
triheteromers, which is similar to themaximal inhibition observed
in Xenopus oocytes (32% ± 1%; Table 1). The findings that
ifenprodil has a markedly slower rate of inhibition, as well as
reduced binding affinity and efficacy at GluN1/GluN2A/GluN2B
triheteromers, compared to GluN1/GluN2B diheteromers sug-
gest structural variation between the ifenprodil binding sites of
triheteromeric and diheteromeric GluN2B-containing NMDA
receptors.
Deactivation Time Course for GluN1/GluN2A/GluN2B
Receptors
GluN2A and GluN2B subunits play distinct physiological roles in
many processes of the central nervous system (Paoletti et al.,
2013). GluN2B is highly expressed early in development,
whereas expression of GluN2A increases during development(Sanz-Clemente et al., 2013). This developmental shift in the
relative expression level of these subunits is accompanied by a
profound change in pharmacological and functional properties
of NMDA receptors. One prominent functional difference is the
deactivation time course, which defines the time course of the
excitatory postsynaptic current (Lester et al., 1990). The time
course of deactivation is in the tens-of-millisecond range for
GluN1/GluN2A diheteromers and in the hundreds-of-millisecond
range for GluN1/GluN2B (Vicini et al., 1998). However, the deac-
tivation kinetics of NMDA receptor EPSCs in hippocampal and
cortical neurons from adult rodents cannot be explained by a
mixture of GluN1/GluN2A and GluN1/GluN2B diheteromers,
suggesting that GluN1/GluN2A/GluN2B triheteromers exist in
these neurons with distinct and intermediate deactivation
kinetics (Gray et al., 2011; Rauner and Ko¨hr, 2011; Tovar et al.,
2013).
We directly measured the deactivation time course
following removal of glutamate for triheteromeric and dihe-
teromeric NMDA receptors expressed in HEK293 cells usingNeuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc. 1091
Table 2. Glutamate Deactivation Time Course of NMDA
Receptors
GluN2 subunits
(coexpressed with
GluN1)
Brief Glutamate Activation (5 ms)
tfast
(ms)
tslow
(ms)
%
Fast
tweighted
(ms) n
WT 2A/2A control 30 ± 1 95 ± 21 78 ± 7 32 ± 1b 11
WT 2A/2A +ifenprodil 30 ± 1 90 ± 23 77 ± 9 34 ± 1 6
WT 2A/2A +Zn2+ 28 ± 1 130 ± 14 72 ± 2 55 ± 2c 6
2AC1/2AC2 control 29 ± 1 102 ± 46 76 ± 9 33 ± 2
b 6
WT 2B/2B control 152 ± 12 496 ± 19 52 ± 2 314 ± 13a 15
WT 2B/2B +ifenprodil 157 ± 9 907 ± 81 55 ± 2 490 ± 33c 6
WT 2B/2B +Zn2+ 147 ± 16 510 ± 27 46 ± 3 343 ± 22 6
2BAC1/2BAC2 control 109 ± 13 422 ± 34 47 ± 8 274 ± 24
a 4
2AC1/2BAC2 control 39 ± 3 146 ± 16 79 ± 4 57 ± 4
a,b 17
2AC1/2BAC2 +ifenprodil 39 ± 4 118 ± 19 66 ± 8 59 ± 4
c 6
2AC1/2BAC2 +Zn
2+ 39 ± 5 153 ± 10 57 ± 3 88 ± 5c 6
NMDA receptors expressed in HEK293 cells were activated by brief
application (5 ms) of 1 mM glutamate in the continuous presence of
100 mM glycine and recorded using whole-cell patch-clamp electrophys-
iology. Responses were activated in the absence (control) or presence of
either 1 mM ifenprodil or 300 nM extracellular Zn2+. Deactivation time
courses were described using dual-exponential fits to obtain tfast and
tslow, and% fast is the fitted percentage of the fast component. Weighted
time constants (tweighted) were calculated as described in Table S2.
Control tweighted were compared using an unpaired t test (two-tailed).
Control tweighted were also compared to tweighted obtained in the presence
of ifenprodil or extracellular Zn2+ for the same cell using a paired t test
(two-tailed). n is the number of cells and all values are mean ± SEM.
See also Figure S6 and Table S2.
aSignificantly different from control at wild-type 2A/2A (p < 0.05).
bSignificantly different from control at wild-type 2B/2B (p < 0.05).
cSignificantly different from control at the same receptor subtype
(p < 0.05).
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptorsfast-application whole-cell patch-clamp recordings. Initially, we
compared the deactivation kinetics following brief (5 ms) pulses
of a supersaturating concentration of glutamate (1 mM) in the
continuous presence of glycine (100 mM). For all receptors, the
deactivation time course was adequately described by a double
exponential function to obtain time constants for fast and slow
components (tfast and tslow), and the weighted time constant
(tweighted) could be calculated using the relative contribution
from each of these components (Table 2). Consistent with the
concentration-response data, neither the presence of the pep-
tide tags nor the GluN2A CTD in GluN2B changed receptor func-
tion, because tweighted was not significantly different between
wild-type 2A/2A and 2AC1/2AC2, or between wild-type 2B/2B
and 2BAC1/2BAC2 (unpaired t test; two-tailed, p > 0.05) (Table
2). The tweighted for glutamate deactivation of wild-type 2A/2A
(32 ± 1 ms; n = 11) was approximately 10-fold smaller than the
corresponding tweighted of wild-type 2B/2B (314 ± 13 ms; n =
15) (Figures 4D and 4E; Table 2). For 2AC1/2BAC2 triheteromers,
tweighted was 57 ± 4 ms (n = 17), which is significantly different
from tweighted values of both wild-type 2A/2A and 2B/2B
(unpaired t test; two-tailed, p < 0.05) (Figures 4D and 4E; Table 2).
Similar results were obtained for all subunit combina-
tions following longer glutamate application (2 s) (Figure S6;1092 Neuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc.Table S2). Thus, we demonstrate that the presence of a single
GluN2A results in a striking acceleration of glutamate deactiva-
tion that endows GluN1/GluN2A/GluN2B triheteromers with a
distinct and intermediate deactivation time course compared
to both GluN1/GluN2A and GluN1/GluN2B diheteromers.
In addition to reducing the response amplitude, it has been
demonstrated that binding of extracellular Zn2+ to GluN2A or
ifenprodil to GluN2B is accompanied by a deceleration of the
deactivation kinetics for GluN1/GluN2A or GluN1/GluN2B dihe-
teromers, respectively (Bhatt et al., 2013; Erreger and Traynelis,
2005; Kew et al., 1996; Paoletti et al., 1997; Tovar and West-
brook, 2012). The change in the kinetics of glutamate responses
mediated bymodulators canmodify the temporal characteristics
of synaptic integration, which could have physiological and
therapeutic relevance. In order to examine the effects of extra-
cellular Zn2+ and ifenprodil on the deactivation kinetics, we
compared responses to brief (5 ms) glutamate applications in
absence of antagonists (control) to responses in the continuous
presence of either 1 mM ifenprodil or 300 nM extracellular Zn2+
obtained from the same cell (i.e., paired recordings). The contin-
uous presence of extracellular Zn2+ significantly increased
tweighted of wild-type 2A/2A from 33 ± 1 ms (control) to 55 ±
2ms (n = 6; paired t test; two-tailed; p < 0.05), whereas ifenprodil
did not change the deactivation time course of wild-type 2A/2A
(Figures 5A and 5C; Table 2). Inhibition of peak responses by
extracellular Zn2+ or ifenprodil is shown in Figure 5B. For wild-
type 2B/2B, ifenprodil significantly increased tweighted from
327 ± 17 ms (control) to 490 ± 33 ms (n = 6; paired t test; two-
tailed; p < 0.05), whereas extracellular Zn2+ had no effect on
the deactivation time course (Figures 5A and 5E; Table 2). Both
in the case of extracellular Zn2+ action on wild-type 2A/2A and
ifenprodil action on wild-type 2B/2B, the slower deactivation
time course is mediated by an increase in the time constant for
the slow component (tslow) without noticeable changes in the
time constant and relative contribution of the fast component
(tfast and % fast) (Table 2).
The presence of ifenprodil resulted in a small, but significant,
increase in tweighted of 2AC1/2BAC2 triheteromers from 55 ±
3 ms (control) to 60 ± 4 ms (n = 6; paired t test; two-tailed;
p < 0.05), whereas extracellular Zn2+ produced a more pro-
nounced increase to 88 ± 5 ms (p < 0.05) (Figures 5A and 5D;
Table 2). Both extracellular Zn2+ and ifenprodil slowed the deac-
tivation time course of 2AC1/2BAC2 triheteromers mainly by
increasing the relative contribution of the slow component
without changing the time constant of the fast component (tfast)
(Table 2). Thus, the presence of a single GluN2A in the trihe-
teromer has a strong effect on both the glutamate deactivation
time course and the capacity of subunit-selective ligands to
robustly modify this time course.
DISCUSSION
Despite thewidespread interest in NMDA receptors as therapeu-
tic targets, it has not been possible to describe the functional or
pharmacological properties of triheteromeric NMDA receptors
that are abundantly expressed in the CNS. The main issue
preventing discoveries on this front has been related to the prob-
lem of expressing a homogenous population of triheteromeric
Figure 5. Effects of Extracellular Zn2+ and Ifenprodil on Deactivation Time Course
(A) The overlay compares representative whole-cell patch-clamp recordings of current responses normalized to the peak amplitude from wild-type 2A/2A (left),
2AC1/2BAC2 triheteromers (middle), and wild-type 2B/2B (right) expressed in HEK293 cells. The receptors were activated by brief pulses (5 ms) of 1mM glutamate
in the absence (control; black line) or presence of 1 mM ifenprodil (red line) or 300 nM extracellular Zn2+ (blue line). Glycine (100 mM) was present at all times.
(B) The bar graph shows the percent inhibition of the peak amplitude by ifenprodil or extracellular Zn2+ relative to control. Each bar represents mean ± SEM from
six cells.
(C–E) The graphs plot theweighted time constants of individual cells expressingwild-type 2A/2A, 2B/2B, and 2AC1/2BAC2 triheteromers. Responses to brief (5ms)
glutamate applications in absence of antagonists (control) were compared to responses in the presence of either 1 mM ifenprodil or 300 nM extracellular Zn2+
obtained from the same cell (i.e., paired recordings). Asterisk denotes significantly different (paired t test; two-tailed, p < 0.05). ns, not significant.
See also Table 2.
Neuron
Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptorsreceptors in heterologous expression systems. Here, we
describe an approach to overcome this obstacle and reveal fea-
tures of GluN1/GluN2A/GluN2B triheteromers that can have
implications for their role in synaptic transmission and for drug
discovery. We estimate that the approach to selectively express
GluN1/GluN2A/GluN2B triheteromers at the cell surface using
engineered C-terminal peptide tags is highly efficient with
<10% of the total current response mediated by GluN1/GluN2A
and GluN1/GluN2B diheteromers. Furthermore, our results
demonstrate that the presence of engineered C-terminal peptide
tags on GluN2 subunits does not modify NMDA receptor func-
tion or pharmacology, thereby enabling stronger conclusions
to be drawn from kinetic and mechanistic studies. GluN1/
GluN2A/GluN2B is the major subtype in hippocampus and cor-
tex of the adult rodent brain (Al-Hallaq et al., 2007; Luo et al.,
1997; Rauner and Ko¨hr, 2011; Sheng et al., 1994; Tovar et al.,
2013), but other triheteromeric NMDA receptors subtypes have
also been identified in the CNS. GluN1/GluN2B/GluN2D is
expressed in cerebellar Golgi cells (Brickley et al., 2003), hippo-
campal granule cells (Pin˜a-Crespo and Gibb, 2002), and sub-
stantia nigra (Jones and Gibb, 2005), whereas GluN1/GluN2A/
GluN2C is found in adult cerebellar granule cells (Cathala et al.,
2000; Chazot et al., 1994). The approach using engineered pep-
tide tags could potentially enable studies on these other, virtually
unexplored, triheteromeric subtypes in heterologous expression
systems. However, given the marked diversity in sequence,
length, and function of the GluN2 CTDs, as well as in the greatlyvarying open probability determined by theGluN2 subunits (Pao-
letti et al., 2013; Sanz-Clemente et al., 2013; Traynelis et al.,
2010), it would likely require optimization of the C-terminal
peptide tags and of the expression system to ensure that only
triheteromeric receptors are functionally expressed at the cell
surface.
We demonstrate a remarkably fast glutamate deactivation of
GluN1/GluN2A/GluN2B triheteromers with a time constant that
is 1.8-fold slower than that of GluN1/GluN2A diheteromers but
5.5-fold faster than that of GluN1/GluN2B diheteromers. This
acceleration mediated by the GluN2A subunit is comparable to
changes observed for NMDA receptor-mediated excitatory
postsynaptic currents (EPSCs) in developing hippocampal and
cortical neurons as GluN2A expression increases with age (Flint
et al., 1997; Gray et al., 2011; Kirson and Yaari, 1996; Stocca and
Vicini, 1998). The strong effect of GluN2A on glutamate deactiva-
tion mirrors the pharmacology, because extracellular Zn2+ in-
hibits GluN1/GluN2A/GluN2B triheteromers and GluN1/GluN2A
diheteromers with similar potency and efficacy in a manner
that appears independent of the GluN2B subunit. By contrast,
both potency and efficacy of GluN2B-selective antagonists
(ifenprodil and CP-101,606) are markedly reduced at GluN1/
GluN2A/GluN2B triheteromers compared to GluN1/GluN2B
diheteromers. Extracellular Zn2+ also mediates a more pro-
nounced deceleration of glutamate deactivation of triheteromers
compared to ifenprodil. The asymmetrical outcome of Zn2+ and
ifenprodil binding on deactivation of triheteromers nicelyNeuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc. 1093
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Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptorsmatches effects on NMDA receptor-mediated EPSCs from
cultured hippocampal neurons suggested to predominantly
express GluN1/GluN2A/GluN2B triheteromers (Tovar et al.,
2013; Tovar and Westbrook, 2012). The striking similarities
between GluN1/GluN2A/GluN2B triheteromers and GluN1/
GluN2A diheteromers with respect to both function and pharma-
cology could render these subtypes indistinguishable under
some experimental conditions and raises the possibility that
the contribution of GluN1/GluN2A diheteromers to synaptic
physiology is overestimated in some studies.
GluN2A and GluN2B subunits interact with different comple-
ments of intracellular proteins, including scaffolding proteins,
and their trafficking is differentially regulated in neurons (Sanz-
Clemente et al., 2013; Traynelis et al., 2010). GluN2A appears
to preferentially reside in synapses, whereas GluN2B can be
found both at synaptic and extrasynaptic sites (Bard and Groc,
2011). In addition, it has been elegantly demonstrated that
GluN2B possesses endocytotic and recycling motifs in the
CTD that dominate sorting of triheteromeric GluN1/GluN2A/
GluN2B receptors; a finding that is supported by the observation
that GluN2B trafficking is unaffected by the absence of GluN2A
expression in GluN2A knockout mice (Tang et al., 2010). The
GluN2A-dependent acceleration of EPSCs that occurs during
development has profound effects on the temporal signaling
properties and charge transfer, both of which have important
consequences for synaptic plasticity. Thus, any triheteromeric
NMDA receptor subtype is likely endowed with a unique com-
bination of trafficking and functional properties tailored to meet
the requirements at a specific subcellular location or a specific
population of cells in the CNS.
The strong influence of GluN2A on glutamate deactivation and
pharmacology of GluN1/GluN2A/GluN2B triheteromers sug-
gests asymmetrical contributions of GluN2A and GluN2B to
long-range allosteric interactions and conformational states of
the receptor. This idea is supported by the significant reduction
of the ifenprodil binding rate to triheteromers compared to
GluN1/GluN2B diheteromers. Our interpretation of this result is
that the GluN2A subunit of GluN1/GluN2A/GluN2B triheteromers
influences the ifenprodil binding pocket at the interface between
ATDs of GluN1 andGluN2B. This would imply that the orientation
or dynamics of the ATDs is different in GluN1/GluN2A/GluN2B
triheteromers compared to GluN1/GluN2B diheteromers. The
possibility of variation between ifenprodil binding pockets
of triheteromers and GluN1/GluN2B diheteromers has important
implications for drug discovery, because this difference could
be exploited for the development of a new generation of thera-
peutic agents that selectively target GluN1/GluN2A/GluN2B
triheteromers.
In summary, we have provided comprehensive assessment of
properties relevant for synaptic signaling and therapeutic manip-
ulation of what may be the most abundant NMDA receptor
subtype in the adult hippocampus and cortex. In doing this, we
developed an approach to study triheteromeric NMDA receptors
and revealed distinct functional and pharmacological features
of GluN1/GluN2A/GluN2B triheteromeric receptors. In the past
decade, the focus on triheteromeric NMDA receptors has
increased significantly as a growing body of biochemical and
anatomical studies has identified triheteromers in most regions1094 Neuron 81, 1084–1096, March 5, 2014 ª2014 Elsevier Inc.of the CNS. The approach and the results described in the pre-
sent study fill a critical gap in our understanding of glutamate
receptors and pave the way for future studies to investigate
the role of different triheteromeric NMDA receptor subtypes in
normal brain function and disease.
EXPERIMENTAL PROCEDURES
DNA Constructs and Ligands
Rat cDNAs for GluN1-1a (GenBank accession number U08261;
hereafter, GluN1), GluN2A (D13211), and GluN2B (U11419) were provided
by Drs. S. Heinemann (Salk Institute) and S. Nakanishi (Osaka Bioscience
Institute). The cDNA encoding rat GluN2B was modified without changing
the amino acid sequence to remove a T7 RNA polymerase termination site
located immediately following transmembrane helix M4 (see the Supplemental
Experimental Procedures). The cDNAs encoding the peptide tags C1 and C2
were custom synthesized (Genscript) and inserted in place of the stop codon
in the open reading frame of GluN2A to generate 2AC1 and 2AC2 (Figure S1).
The CTD of the GluN2B subunit was then replaced by the CTD of the GluN2A
subunits 2AC1 and 2AC2. Residues 1–844 of resulting chimeric subunits,
denoted 2BAC1 and 2BAC2, were identical to GluN2B, and the remaining
residues were identical to residues 844–1541 and 844–1533 from 2AC1 and
2AC2, respectively. All GluN2 cDNAs were inserted into the pCI-neo vector
(Promega). The pCI-neo vector was used to express GluN1 in Xenopus
oocytes, whereas the GluN1 cDNA was under the control of the inducible
promoter in the pTRE-tight vector for expression in HEK293 Tet-On Advanced
cells (Clontech). In addition, cDNA encoding EGFP was inserted between
the inducible promoter and the open reading frame of GluN1 (EGFP and
GluN1 were not expressed as a fusion protein) in order to reduce expression
of GluN1 and obtain a linear relationship between EGFP and GluN1 expres-
sion. Amino acids are numbered according to full-length protein, including
the signal peptide. See the Supplemental Experimental Procedures for full
details.
Two-Electrode Voltage-Clamp Recordings
Preparation and injection of Xenopus oocytes were performed essentially as
previously described (Hansen et al., 2013). For experiments using tagged
GluN2 subunits, the cRNAs encoding GluN1, as well as C1- and C2-tagged
GluN2, were injected at a 1:6:6 ratio at a total volume of 50 nl. For all
experiments, the cRNA was diluted with RNase-free water to a concentration
that would result in 10 ng of total injected cRNA. See the Supplemental
Experimental Procedures for full details.
Whole-Cell Patch-Clamp Recordings
HEK293 Tet-On Advanced cells (Clontech) were transfected with plasmid
cDNAs encoding GluN1 (together with EGFP in the pTRE-tight vector) and
GluN2 subunits at a ratio of 1:2 using the calcium phosphate precipitation
method as previously described (Hansen et al., 2013). To minimize cyto-
toxicity, the culture medium was supplemented with NMDA receptor antago-
nists D,L-2-amino-5-phosphonovalerate (200 mM) and 7-chlorokynurenic acid
(200 mM). In addition, 5 ng/ml doxycycline was added to the medium to induce
low-level expression of GluN1. Experiments were performed approximately
24 hr following transfection. For experiments on triheteromeric receptors, it
was important to only include cells with current responses less than
1,000 pA in order to minimize overexpression, which has the potential to
circumvent the ER retention signals in the engineered peptide tags. Lower
expression levels (i.e., current responses less than 1,000 pA) improved the
ability of the cell to control trafficking and selectively express triheteromeric
receptors at the cell surface. See the Supplemental Experimental Procedures
for full details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2014.01.035.
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